I suspect all the Maintena reps who were rejected by Alkermes will be working at 200% to shut Lauroxil down and out. (I, for one). Alkermes may have taken some good ones (from what I hear, more from the Lundbeck side), but they left a lot of good ones behind, and while the product may not be a powerful force, yet, WE are. ALK just did Otsuka a favor by treating some of their people this way. With our 3 year advantage AND that ALK is clearly hiring a lot of tablet reps (Latuda, former Fanapt, etc......Ummm, no comparison, huge learning curve) as well as injection reps from other therapeutic areas (again, no comparison....there is nothing out there like this...and most of them will quit in time as result, as happened to Otsuka managers who hired hospital reps from other companies because psych is not your typical hospital sales, and they hated it), they just set themselves back. They'll see. And so will we